Trehalose (DB12310): A Comprehensive Monograph on a Bioprotectant Molecule from Excipient to Emerging Therapeutic

Executive Summary

Trehalose (DrugBank ID: DB12310) is a naturally occurring disaccharide that presents a compelling and paradoxical profile in the biopharmaceutical landscape. It is simultaneously a well-established, high-purity pharmaceutical excipient with an exceptional safety record and an investigational therapeutic agent with significant potential, particularly in neurodegenerative and ophthalmic diseases. This report provides a comprehensive analysis of Trehalose, synthesizing its physicochemical properties, complex pharmacology, clinical development status, safety profile, and global regulatory standing to provide a strategic perspective on its future.

The foundational characteristic of Trehalose is the exceptional stability of its α,α-1,1-glycosidic bond, which confers resistance to heat and acid hydrolysis. This property underpins its primary biological function as a bioprotectant, enabling organisms to survive extreme environmental stress, and makes it an ideal stabilizer for sensitive biologic drugs. As a therapeutic, Trehalose is being investigated for its potential to clear pathological protein aggregates implicated in neurodegenerative disorders such as spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.

However, its therapeutic rationale is complicated by a central scientific controversy regarding its primary mechanism of action. While the prevailing hypothesis posits that Trehalose induces autophagy to clear cellular debris, a substantial body of evidence from in vitro studies suggests it may instead block autophagic flux. This mechanistic ambiguity represents a critical risk for its development in systemic diseases and points toward alternative or indirect mechanisms, such as modulation of the gut-brain axis.

The molecule's development is further defined by a significant pharmacokinetic challenge: upon oral administration, it is almost entirely metabolized to glucose by the intestinal enzyme trehalase, resulting in negligible systemic bioavailability of the intact molecule. This limitation has created two divergent development paths. The first is a successful, low-risk strategy of local delivery, exemplified by its proven efficacy in ophthalmic solutions for Dry Eye Syndrome, where it directly protects the ocular surface. The second is a high-risk, high-reward pursuit of systemic therapies for neurodegenerative diseases, which necessitates parenteral (intravenous) administration to achieve systemic exposure and relies on regulatory incentives such as Orphan Drug and Fast Track designations to navigate its complex development.

Ultimately, the trajectory of Trehalose as a systemic therapeutic hinges on three critical factors: definitive elucidation of its in vivo mechanism of action, the successful completion of ongoing pivotal trials in rare neurodegenerative diseases, and potentially the development of advanced drug delivery systems to improve target engagement. Its unparalleled safety profile provides a robust foundation, but overcoming the profound pharmacological and pharmacokinetic hurdles will be essential to fully realize its therapeutic promise beyond its established roles.

1. Molecular Profile and Physicochemical Characteristics

A comprehensive understanding of Trehalose begins with its fundamental molecular identity and the unique physicochemical properties that dictate its biological functions and industrial applications.

1.1. Identification and Nomenclature

Trehalose is systematically identified across multiple chemical and biological databases, ensuring its unambiguous characterization.

• Primary Identifiers: The molecule is universally recognized by its common name, Trehalose. In the DrugBank database, it is assigned the accession number DB12310.[1] Its Chemical Abstracts Service (CAS) Registry Number is 99-20-7.[1]
• Synonyms and Alternate Names: It is frequently referred to by several synonyms that reflect its structure and historical discovery. These include α,α-Trehalose, D(+)-Trehalose, Mycose, and Tremalose.[3] Its chemical name is α-D-Glucopyranosyl-α-D-glucopyranoside.[3]
• Systematic Naming: The International Union of Pure and Applied Chemistry (IUPAC) name provides a precise structural description: (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-oxyoxane-3,4,5-triol.[1]
• Database Cross-references: Trehalose is extensively cataloged in major scientific databases, including ChEBI (ID: 16551), ChEMBL (ID: CHEMBL1236395), the Human Metabolome Database (HMDB ID: HMDB0000975), and the Kyoto Encyclopedia of Genes and Genomes (KEGG ID: C01083).[1] This broad registration underscores its significance as a metabolite and small molecule of interest.

1.2. Chemical Structure, Stability, and Properties

The molecular architecture of Trehalose is the source of its remarkable stability and bioprotective capabilities.

• Structure: Trehalose is a non-reducing disaccharide composed of two α-D-glucose units. Its defining feature is the α,α-1,1-glycosidic bond that links the anomeric carbons of the two glucose molecules.[1] This symmetrical linkage distinguishes it from other common disaccharides like sucrose (α-1,β-2 linkage) or maltose (α-1,4 linkage).
• Molecular Formula and Weight: The chemical formula for anhydrous Trehalose is C12​H22​O11​, corresponding to a molecular weight of 342.30 g/mol.[1]
• Chemical Stability: The α,α-1,1-glycosidic bond is characterized by a very low free energy (less than 1 kcal/mol), in stark contrast to the bond in sucrose (27 kcal/mol).[8] This inherent stability confers exceptional resistance to acid hydrolysis and high temperatures.[8] For example, after one hour in a solution at pH 3.5, over 99% of Trehalose remains intact, whereas sucrose is almost completely hydrolyzed under the same conditions.[11] As a non-reducing sugar, its closed-ring structure prevents the aldehyde end groups from reacting with amino acid residues on proteins, a detrimental process known as glycation.[9] This chemical inertness is not merely a technical detail but the core property that enables its utility. This stability is what allows it to function as a reliable cryoprotectant in pharmaceutical formulations, where it must withstand processing and storage conditions without degrading into reactive byproducts.[9] Concurrently, this same stability allows it to accumulate in organisms under extreme environmental stress, where it serves its natural bioprotective function without being prematurely metabolized.[4] Thus, its value as both a pharmaceutical excipient and a natural stress protectant originates from this single molecular feature.
• Computed Properties: Computational analysis reveals properties consistent with a highly polar and hydrophilic molecule. Key descriptors include a calculated partition coefficient (XLogP3-AA) of -4.2, 8 hydrogen bond donors, 11 hydrogen bond acceptors, and a topological polar surface area (TPSA) of 190 A˚2.[1] These values quantitatively describe its strong affinity for water and its potential for extensive hydrogen bonding with biological macromolecules.

1.3. Spectroscopic and Physical Data

Empirical data from physical and spectroscopic analyses confirm the identity and purity of Trehalose.

• Physical Description: In its solid form, Trehalose is a white to off-white, virtually odorless crystalline powder with a mild sweet taste, possessing approximately 45% of the sweetness of sucrose.[1] It is most commonly available commercially as a stable dihydrate ( C12​H22​O11​⋅2H2​O).[1]
• Melting Point: The anhydrous form of Trehalose has a high melting point of 203°C.[1] The dihydrate form exhibits a more complex thermal behavior, first melting at approximately 97°C, then losing its water of crystallization and resolidifying at 130°C before the anhydrous form melts.[12]
• Spectroscopic Data: The structure of Trehalose has been unequivocally confirmed by Nuclear Magnetic Resonance (NMR) spectroscopy. Publicly available [1H,13C] 2D NMR spectral data, acquired at 600 MHz in a water solvent, provide a detailed fingerprint of the molecule, confirming the connectivity and stereochemistry of the two glucose units consistent with its assigned structure.[1]

Table 1.1: Key Physicochemical and Structural Identifiers of Trehalose

Property	Value / Identifier	Source(s)
DrugBank ID	DB12310	1
CAS Number	99-20-7	1
IUPAC Name	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-oxyoxane-3,4,5-triol	1
SMILES	C([C@@H]1C@HO)O
InChIKey	HDTRYLNUVZCQOY-LIZSDCNHSA-N
Molecular Formula	C12​H22​O11​
Molecular Weight	342.30 g/mol (anhydrous)
Physical Form	White or nearly white crystalline powder
Melting Point	203°C (anhydrous)
Hydrogen Bond Donors	8
Hydrogen Bond Acceptors	11
Topological Polar Surface Area	190 A˚2

2. Pharmacology and Mechanism of Action

The pharmacological profile of Trehalose is multifaceted, rooted in its fundamental bioprotective properties and extending to complex cellular processes relevant to human disease, most notably neurodegeneration.

2.1. Foundational Bioprotective and Stabilizing Functions

The primary and most well-understood role of Trehalose is as a potent bioprotectant, a function it serves across a vast range of non-mammalian organisms.

• Anhydrobiosis and Stress Protection: Trehalose is synthesized by bacteria, fungi, plants, and invertebrates as a defense mechanism against severe environmental stress. It is a key molecule in anhydrobiosis, the ability of an organism to survive near-complete dehydration for extended periods and subsequently reanimate upon rehydration. This protection extends to other stressors, including extreme heat, cold, and oxidative damage.
• Mechanisms of Stabilization: The protective effects of Trehalose are attributed to a combination of physical mechanisms that stabilize biological structures at the molecular level. Three primary hypotheses have been proposed :

1. Water Replacement: In dehydrated conditions, Trehalose molecules are thought to form hydrogen bonds directly with the polar groups of proteins and lipid membranes, effectively acting as a surrogate for water and preserving the native conformation of these macromolecules.
2. Vitrification (Glass Transition): Trehalose has the highest glass transition temperature (Tg​) among disaccharides (110-120°C). Upon drying, it can form a stable, non-crystalline, glassy matrix. This vitrified state immobilizes proteins and membranes, preventing denaturation, aggregation, and fusion that would otherwise occur under stress.
3. Chemical Stability: As a non-reducing sugar, Trehalose does not participate in glycation reactions, thereby preventing the non-enzymatic damage to proteins that can occur with reducing sugars.

2.2. Neuroprotection and Clearance of Pathological Protein Aggregates

Building on its protein-stabilizing properties, Trehalose has emerged as a promising therapeutic candidate for neurodegenerative diseases, which are often characterized by the pathological misfolding and aggregation of specific proteins.

• Targeting Protein Misfolding: Preclinical research has demonstrated that Trehalose can inhibit the aggregation and promote the clearance of key pathogenic proteins. These include amyloid-beta (Aβ) and hyperphosphorylated tau in models of Alzheimer's disease; alpha-synuclein (α-synuclein) in models of Parkinson's disease; and mutant huntingtin (mHTT) in models of Huntington's disease.
• Chaperone-like Activity: Beyond simply preventing aggregation, Trehalose has been shown to exhibit properties of a chemical chaperone, capable of assisting in the refolding of partially denatured proteins back to their functional state. This suggests a more active role in maintaining cellular proteostasis.

2.3. The Autophagy Controversy: A Critical Analysis of an mTOR-Independent Pathway

The central and most debated mechanism underlying Trehalose's neuroprotective effects is its interaction with autophagy, the cellular process for degrading and recycling damaged organelles and misfolded proteins.

• The Autophagy Induction Hypothesis: The prevailing theory, supported by numerous animal studies, is that Trehalose protects neurons by inducing autophagy. This induction is thought to occur via a pathway independent of the master metabolic regulator mTOR (mechanistic target of rapamycin). Some evidence suggests Trehalose achieves this by activating Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. In animal models of neurodegeneration, administration of Trehalose has been associated with reduced levels of protein aggregates and increased levels of autophagy markers, seemingly confirming this hypothesis.
• The Autophagy Flux Blockage Counter-Hypothesis: Despite the compelling in vivo data, a significant and growing body of evidence from in vitro cell culture studies presents a contradictory view. These studies suggest that Trehalose does not induce autophagy but instead blocks or inhibits the autophagic flux. Autophagic flux is the complete process from the formation of an autophagosome to its fusion with a lysosome and the subsequent degradation of its contents. A blockage in this process, for instance at the fusion step, would also lead to an accumulation of autophagosomes and the associated marker protein LC3-II, which can be mistakenly interpreted as autophagy induction. Rigorous experiments using tandem fluorescent reporters (e.g., mRFP-GFP-LC3) have shown that Trehalose treatment increases autophagosomes but not functional autolysosomes, indicating a disruption in the pathway.
• Reconciling the Discrepancy: This conflict between in vivo and in vitro findings represents the single greatest scientific risk to the development of Trehalose for systemic neurodegenerative diseases. The entire therapeutic rationale for its use in conditions like Alzheimer's and Parkinson's is predicated on its ability to clear toxic proteins, with autophagy induction being the proposed mechanism. If the flux blockage mechanism observed in cell culture is what truly occurs, then the beneficial effects seen in animal models must be attributed to a different, as-yet-unidentified direct mechanism, or they may be entirely indirect. This fundamental mechanistic ambiguity must be resolved to provide a solid foundation for its clinical development. Potential explanations for the discrepancy include differences in dose and exposure time between cell culture and animal models, or the possibility that the in vivo effects are not a direct result of Trehalose acting on neurons at all.

2.4. Ancillary Pharmacodynamic Effects: Antioxidant, Anti-inflammatory, and Gut-Brain Axis Modulation

Beyond the autophagy debate, Trehalose exerts its effects through several other biologically relevant pathways.

• Antioxidant Properties: Trehalose has demonstrated the ability to mitigate oxidative stress, a common pathological feature in both neurodegeneration and ophthalmic conditions. This effect is proposed to arise from its capacity to scavenge damaging reactive oxygen species (free radicals).
• Anti-inflammatory Effects: In models of neuroinflammation, Trehalose has been shown to suppress the release of pro-inflammatory cytokines and inhibit the activation of the inflammasome, a key component of the innate immune response. This suggests it may help dampen the chronic inflammatory state that contributes to neuronal damage.
• Gut-Brain Axis Modulation: An emerging and highly significant hypothesis seeks to explain how orally administered Trehalose can exert neuroprotective effects despite its poor absorption and limited ability to cross the blood-brain barrier. This theory posits that Trehalose acts indirectly by modulating the composition and function of the gut microbiota. The altered microbiome could then send signals to the central nervous system via various pathways, including the vagus nerve or the release of metabolites and neurotransmitters. This hypothesis represents a paradigm shift in the conceptual framework for Trehalose's development. If correct, the critical pharmacokinetic parameters would no longer be plasma concentration and brain penetration, but rather intestinal lumen concentration and specific effects on microbial populations. This would fundamentally alter formulation and dosing strategies, potentially favoring oral delivery systems designed for gut targeting over parenteral routes. This model also elegantly explains experimental findings where oral, but not intraperitoneal, administration of Trehalose produced neuroprotective effects, strongly implicating a gastrointestinal-mediated mechanism.

3. Pharmacokinetics, Metabolism, and Bioavailability

The pharmacokinetic profile of Trehalose is dominated by its interaction with the enzyme trehalase, a characteristic that profoundly influences its absorption, distribution, and ultimate therapeutic application, dictating the entire strategy for its clinical development.

3.1. Absorption and the Impact of Intestinal Trehalase

The primary obstacle to the systemic delivery of intact Trehalose via the oral route is its rapid and efficient enzymatic degradation in the gastrointestinal tract.

• Enzymatic Degradation: Humans, like most omnivores, possess the enzyme trehalase (α,α-trehalose glucohydrolase) located at the brush border of the intestinal mucosa. Upon ingestion, this enzyme rapidly hydrolyzes Trehalose into two individual glucose molecules, which are then absorbed into the bloodstream.
• Low Systemic Absorption: As a direct consequence of this efficient hydrolysis, the systemic absorption of the intact Trehalose disaccharide after oral administration is extremely low. Studies suggest that only a minute fraction, estimated at approximately 0.5%, may be absorbed via passive diffusion. Therefore, for all practical purposes, oral Trehalose functions as a pro-drug for glucose in terms of systemic exposure, while delivering the intact molecule primarily to the gut lumen. This fundamental pharmacokinetic property necessitates two completely separate and divergent therapeutic development strategies. The first is a low-risk path focused on local or topical applications, such as the successful development of ophthalmic solutions for dry eye, where the drug is delivered directly to the target tissue, completely bypassing the issue of first-pass gut metabolism. The second is a higher-risk, more complex path for systemic diseases like neurodegeneration, which forces developers to use parenteral (e.g., intravenous) routes of administration to circumvent gut metabolism and achieve meaningful systemic concentrations of the intact molecule. These two approaches treat Trehalose as functionally different drugs, defined entirely by their route of delivery and the pharmacokinetic barriers they are designed to overcome.

3.2. Distribution and Blood-Brain Barrier Permeability

For systemically administered Trehalose, its distribution throughout the body and its ability to reach the central nervous system (CNS) are critical for efficacy in neurological disorders.

• Systemic Distribution: Following parenteral administration (e.g., intramuscular or intravenous), Trehalose is distributed systemically. A pharmacokinetic study in rats after intramuscular injection reported a volume of distribution (Vd​) of 1.403 L/kg, suggesting distribution into tissues beyond the plasma volume.
• Blood-Brain Barrier (BBB) Permeability: The ability of Trehalose to cross the BBB is a point of critical importance and some uncertainty. While some preclinical data and reviews suggest it can cross the BBB, its highly hydrophilic nature and molecular size (342.3 Da) present significant challenges to efficient transport into the brain parenchyma. Achieving therapeutically effective concentrations within the CNS is a major hurdle for systemic administration and is a key rationale for the use of high-dose intravenous infusions in ongoing clinical trials for neurodegenerative diseases. The lack of robust, publicly available human data on the cerebrospinal fluid (CSF) to plasma concentration ratio for Trehalose represents a significant knowledge gap and a potential risk for these late-stage clinical programs.

3.3. Metabolism and Excretion

The metabolism and elimination of systemically available Trehalose are rapid, involving further enzymatic cleavage and renal excretion.

• Primary Metabolism: The principal metabolic fate of orally administered Trehalose is its hydrolysis to glucose in the small intestine, as described above.
• Renal Trehalase and Excretion: In addition to the gut, humans also express trehalase in the kidneys, specifically in the brush border of the proximal tubular cells. Systemically circulating Trehalose that is filtered by the glomerulus can be cleaved to glucose in the kidney or excreted unchanged in the urine. However, excretion of the intact molecule appears to be minimal; one human infusion study reported that only about 1% of the infused dose was recovered in the urine, suggesting highly efficient systemic or renal metabolism. A pharmacokinetic study in rats reported a short elimination half-life ( t1/2​) of 0.73 hours and a high clearance (CL) of 1.331 L/h/kg, confirming its rapid removal from circulation.

3.4. Comparative Analysis of Administration Routes and Formulation Strategies

The choice of administration route fundamentally dictates the pharmacokinetic profile and, consequently, the biological effects of Trehalose.

• Oral Administration: This route results in high concentrations of intact Trehalose within the gastrointestinal lumen, where it can interact with the gut microbiota, followed by systemic delivery of its breakdown product, glucose. It is therefore a suitable route for investigating gut-mediated effects but not for achieving systemic exposure to the parent drug.
• Parenteral Administration: Intravenous (IV) or intramuscular (IM) injection bypasses intestinal trehalase, allowing for controlled systemic exposure to the intact Trehalose molecule. This is the required route for treating systemic or CNS diseases where direct action of the disaccharide is hypothesized.
• Local Delivery: Topical application, such as ophthalmic solutions, delivers high concentrations of Trehalose directly to the target tissue (the ocular surface) without significant systemic absorption or metabolism. This approach maximizes local efficacy while avoiding systemic pharmacokinetic challenges, explaining its success in this therapeutic area.

4. Clinical Development and Therapeutic Applications

The clinical development of Trehalose is characterized by a dual identity: it is a widely used and well-characterized pharmaceutical excipient, while also being actively investigated as a novel therapeutic agent across a diverse range of indications, most prominently in neurodegenerative and ophthalmic diseases.

4.1. Neurodegenerative Disorders: A High-Potential, High-Challenge Arena

Trehalose is being pursued as a disease-modifying therapy for several debilitating neurodegenerative disorders, a strategy heavily supported by regulatory incentives for rare diseases which help to de-risk the inherently challenging and costly process of CNS drug development. By first targeting orphan indications like SCA and ALS, developers can potentially achieve a faster path to market, leveraging benefits such as market exclusivity and enhanced regulatory engagement. This approach is a classic and capital-efficient biotech strategy for repurposing a molecule with a known safety profile for a novel, high-unmet-need indication.

4.1.1. Spinocerebellar Ataxia (SCA)

SCA, particularly SCA Type 3 (SCA3), is a lead indication for the intravenous formulation of Trehalose developed by Seelos Therapeutics.

• Regulatory Status: The program has received significant regulatory support from the U.S. Food and Drug Administration (FDA), including Orphan Drug designation for the treatment of SCA3 and Fast Track designation for the broader SCA indication.
• Clinical Trials: Early clinical evidence from an open-label Phase 2a study was encouraging, showing that patients treated with IV Trehalose had stable scores on the Scale for Assessment and Rating of Ataxia (SARA) over 6 to 12 months. This outcome is favorable when compared to natural history data, which would predict a measurable worsening of symptoms over the same period. Based on these results, a global, placebo-controlled Phase 2b/3 study (STRIDES, NCT05490563) has been initiated. This pivotal trial is evaluating a 90.5 mg/mL intravenous infusion of Trehalose. Concurrently, a separate study ( NCT04399265) is investigating the efficacy of oral Trehalose in SCA3 patients. The parallel investigation of both IV and oral routes provides a unique opportunity for a direct clinical comparison of the competing mechanistic hypotheses—a direct CNS effect requiring systemic exposure versus an indirect, gut-mediated effect. The relative outcomes of these trials could provide the most definitive human evidence to date to help resolve this central scientific question.

4.1.2. Amyotrophic Lateral Sclerosis (ALS)

Trehalose is also being evaluated as a potential treatment for ALS, another devastating neurodegenerative disease.

• Regulatory Status: The therapeutic program for ALS has been granted Orphan Drug designation by both the FDA and the European Medicines Agency (EMA), highlighting the significant unmet medical need.
• Clinical Trials: Trehalose is being studied as Regimen E within the innovative HEALEY ALS Platform Trial (NCT05136885). This Phase 2b/3 study is designed to efficiently evaluate multiple investigational therapies simultaneously. The Trehalose arm will enroll approximately 160 patients with either familial or sporadic ALS, who will receive the drug via intravenous infusion over a 24-week period. The primary endpoint is the change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score, a standard measure of functional decline in ALS.

4.1.3. Alzheimer's and Parkinson's Diseases

Investigations into Trehalose for the most common neurodegenerative diseases are at an earlier stage of clinical development.

• Alzheimer's Disease (AD): A Phase 1 clinical trial, known as the MASHIANE study (NCT04663854), is underway to evaluate the safety and potential efficacy of weekly 15 g intravenous infusions of Trehalose over a 12-week period in patients with AD. The scientific rationale is based on preclinical evidence suggesting Trehalose can inhibit the formation of β-amyloid plaques, a key pathological hallmark of AD.
• Parkinson's Disease (PD): A Phase 4 trial (NCT05355064) is assessing the efficacy of daily 4 g oral administration of Trehalose. The study includes two cohorts of patients: those with idiopathic PD and those with PD caused by the LRRK2 G2019S mutation, a common genetic risk factor for the disease. This trial will provide valuable data on the potential of the oral route, likely testing the gut-brain axis hypothesis.

4.1.4. Other Investigational CNS Uses

• Huntington's Disease (HD): Preclinical models have shown that Trehalose can reduce the aggregation of the mutant huntingtin protein, and it is cited as being in development for HD, though specific clinical trial identifiers are not provided in the available materials.
• Bipolar Depression: A randomized, placebo-controlled trial (NCT02800161) has been completed. This study investigated high-dose oral Trehalose (70 g) as an adjunctive treatment to lithium in patients with bipolar depression, based on the hypothesis that its autophagy-enhancing properties could be beneficial.

Table 4.1: Summary of Key Clinical Trials for Trehalose in Neurodegenerative Diseases

4.2. Ophthalmic Formulations for Dry Eye Syndrome: A Proven Application

In stark contrast to the challenges of systemic delivery, the topical application of Trehalose in ophthalmology represents a proven and commercially successful therapeutic area.

• Mechanism of Action: In the context of Dry Eye Syndrome (DED), Trehalose functions as a bioprotectant and osmoprotectant on the ocular surface. It stabilizes the cell membranes of corneal and conjunctival epithelial cells, protecting them from damage caused by desiccation and tear hyperosmolarity. It also helps retain moisture in the tear film and has been shown to reduce ocular surface inflammation.
• Clinical Efficacy: A robust body of evidence from multiple randomized controlled trials (RCTs) confirms that Trehalose-containing ophthalmic solutions are safe and effective for the treatment of moderate to severe DED. These studies consistently show significant improvements in patient-reported symptoms (measured by the Ocular Surface Disease Index, OSDI), as well as objective clinical signs such as tear film breakup time (TBUT), Schirmer's test, and ocular surface staining scores.
• Commercial Products: Trehalose is often formulated in combination with other hydrating agents, most notably sodium hyaluronate. Commercially available products include Thealoz Duo and TheraTears EXTRA. These preservative-free formulations are well-tolerated and suitable for long-term use.
• Perioperative Use: The benefits of Trehalose eye drops also extend to the surgical setting. Studies have shown that their use before and after cataract surgery can effectively reduce the signs and symptoms of postoperative DED, a common complication of the procedure.

4.3. Established Role as a Pharmaceutical Excipient and Cryoprotectant

Beyond its investigational therapeutic uses, Trehalose has a long-standing and critical role as a high-value excipient in the biopharmaceutical industry.

• Biologic Stabilization: High-purity, low-endotoxin grades of Trehalose are widely used to stabilize sensitive biological molecules during formulation, freeze-drying (lyophilization), and long-term storage. Its ability to form a stable glassy matrix and prevent protein aggregation makes it an ideal excipient for products such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion proteins, peptides, and vaccines.
• Commercial Examples: Trehalose is a component in the formulations of several blockbuster biologic drugs, including Herceptin® (trastuzumab), Avastin® (bevacizumab), and Lucentis® (ranibizumab), underscoring its importance and regulatory acceptance.
• Cryopreservation: Its bioprotective properties are also leveraged in the cryopreservation of human cells. It is used in media to protect cells like platelets and stem cells from damage during the freeze-thaw process, improving their viability and function upon recovery.

5. Safety, Tolerability, and Toxicology Profile

Trehalose possesses an extensive and well-documented safety profile, characterized by very low toxicity. This strong safety record is a significant strategic asset, substantially de-risking its development as a pharmaceutical agent compared to a new chemical entity. Most new drug candidates face considerable toxicology hurdles, but Trehalose benefits from decades of safe human consumption as a food ingredient and rigorous evaluation by global food safety authorities.

5.1. Human Safety and Tolerability Data

Extensive human data support the safety of Trehalose.

• General Safety: It is considered safe for human consumption, a conclusion supported by numerous dedicated safety studies and its long history of use in food products, particularly in Japan. Studies have shown that single doses of up to 50 g are well-tolerated by most individuals.
• Regulatory Assessment: The Joint FAO/WHO Expert Committee on Food Additives (JECFA), a leading international body for food safety assessment, has evaluated Trehalose and allocated an Acceptable Daily Intake (ADI) of "not specified". This is the safest category, reserved for food substances of very low toxicity for which the total dietary intake, at the levels necessary to achieve the desired effect, is not considered to represent a hazard to health.

5.2. Adverse Event Profile: Focus on Gastrointestinal Effects

The adverse event profile of Trehalose is well-defined, predictable, and benign, centering on manageable gastrointestinal effects. This presents a significant advantage over many CNS drugs, which often have complex and severe side effect profiles.

• Primary Side Effects: The most common, and essentially only, reported adverse effects are gastrointestinal in nature. These include flatulence, abdominal distension, borborygmus (rumbling sounds), and diarrhea. These symptoms are dose-dependent and typically occur following the ingestion of a large single dose.
• Laxative Threshold: The mechanism for these effects is osmotic. When a large amount of Trehalose is ingested, it may overwhelm the digestive capacity of the intestinal trehalase enzyme. The undigested sugar then draws water into the intestinal lumen, leading to osmotic diarrhea. The transitory laxative threshold has been estimated to be approximately 0.65 g/kg of body weight, which corresponds to about 39 g for a 60 kg individual.

5.3. Special Populations and Contraindications: Trehalase Deficiency

The primary contraindication for Trehalose is a rare genetic condition that makes risk management in clinical trials and practice straightforward.

• Mechanism: A small subset of the population has a hereditary or acquired deficiency of the trehalase enzyme. In these individuals, the inability to properly digest Trehalose leads to malabsorption and the onset of gastrointestinal symptoms at much lower doses than in the general population. This is physiologically analogous to lactose intolerance in individuals with lactase deficiency.
• Prevalence: Trehalase deficiency is generally very rare. However, its prevalence is notably higher in certain isolated populations, such as the Greenlandic Inuit, where it may affect 8-15% of individuals.

5.4. Preclinical Toxicology and Genotoxicity Assessment

A comprehensive battery of preclinical studies has confirmed the lack of systemic toxicity of Trehalose.

• Animal Toxicology: Multiple oral toxicity studies in various animal species, including mice, rats, and dogs, have been conducted. Even at high doses, such as when Trehalose constituted up to 10% of the diet, these studies found no consistent, treatment-related, or dose-dependent adverse effects.
• Genotoxicity: Trehalose has been evaluated in a standard battery of genotoxicity assays to assess its potential to cause genetic mutations. The results were negative in the bacterial reverse mutation test (Ames test), the in vitro chromosomal aberration test in Chinese hamster ovary cells, and the in vivo micronucleus formation test in mice. These findings indicate that Trehalose does not have mutagenic or clastogenic potential.

5.5. Drug-Drug Interaction Potential

The potential for clinically significant drug-drug interactions with Trehalose appears to be very low.

• Known Interactions: The available literature indicates that there are no known drug-drug interactions for orally administered Trehalose. Since its primary metabolic fate is hydrolysis to glucose, any potential interactions would theoretically be related to those of glucose, such as effects on glycemic control in diabetic patients on anti-hyperglycemic medications. However, this has not been specifically reported as a clinical issue for Trehalose itself. Its use as an excipient in numerous approved biologic drugs further supports its low interaction potential.

6. Global Regulatory Landscape

Trehalose occupies a unique position in the global regulatory environment, with distinct and parallel classifications as a food ingredient, a pharmaceutical excipient, and an investigational therapeutic agent. This dual status provides both a strong precedent for safety and a viable, incentivized pathway for novel therapeutic development.

6.1. United States (FDA)

In the United States, Trehalose is regulated differently depending on its intended use.

• Food Ingredient Status: Trehalose is classified as Generally Recognized As Safe (GRAS) for use as an ingredient in a wide variety of food products. The FDA responded with a "No questions" letter to GRAS Notice No. GRN 000045 in October 2000, affirming its safety for food use. A subsequent GRAS notice (GRN 000912) for expanded uses was withdrawn by the notifier after the FDA requested additional data, particularly concerning the safety of very high estimated dietary exposures (up to 85 g/person/day) and the safety of enzymes used in a new manufacturing process. This interaction highlights a potential friction point where high therapeutic doses could blur the line between food and drug, potentially attracting greater regulatory scrutiny of cumulative exposure from all sources.
• Therapeutic Agent Status: As an investigational drug, Trehalose is actively regulated by the FDA's Center for Drug Evaluation and Research (CDER). It has successfully leveraged pathways for rare diseases, receiving multiple Orphan Drug designations (for SCA3 and ALS) and Fast Track designation (for SCA). These designations provide significant development incentives, including market exclusivity, tax credits, and expedited review processes.

6.2. European Union (EMA)

The regulatory framework in the European Union mirrors that of the U.S., with separate pathways for food and medicinal products.

• Food Ingredient Status: Trehalose was authorized for placing on the market as a "novel food" or "novel food ingredient" by a Commission Decision in 2001, under Regulation (EC) No 258/97. Food products containing it must include a statement on the label indicating that "Trehalose is a source of glucose".
• Therapeutic Agent Status: The European Medicines Agency (EMA) has also granted Orphan Drug designations for Trehalose for therapeutic indications, including SCA3 and ALS, recognizing its potential to treat rare, life-threatening conditions.
• Pharmaceutical Excipient: Pharmaceutical-grade Trehalose conforms to the standards of the European Pharmacopoeia (EP), permitting its use as an excipient in medicinal products marketed in the EU.

6.3. Japan (MHLW/PMDA) and Other Key Regions

Japan has a long history with Trehalose, as it was the first country to develop a method for its mass production.

• Japan: Trehalose is approved as a food additive by the Ministry of Health, Labour and Welfare (MHLW) and has been widely used in the Japanese food industry for decades. It is also listed in the Japanese Pharmacopoeia (JP), establishing its quality standards for use as a pharmaceutical excipient.
• Other Regions: Reflecting its strong global safety record, Trehalose is approved for use in food products in over 60 countries worldwide, including Canada (Health Canada), Australia/New Zealand (FSANZ), China (MOH), and South Korea.

Table 6.1: Comparative Global Regulatory Status of Trehalose

7. Synthesis, Emerging Technologies, and Future Outlook

The future of Trehalose as a therapeutic agent is contingent on overcoming its inherent pharmacokinetic limitations and resolving key mechanistic questions. The field is actively exploring innovative solutions, from advanced drug delivery systems to the synthesis of novel analogues, to unlock its full potential.

7.1. Commercial Production and Synthesis

The widespread availability and commercial viability of Trehalose are the result of a key innovation in its production. While naturally occurring, extraction was not scalable. The breakthrough came with the development of a multi-step enzymatic process that produces high-purity Trehalose from liquefied starch. This method, pioneered in Japan, made large-scale production economically feasible, enabling its broad use in the food, cosmetic, and pharmaceutical industries.

7.2. Advanced Drug Delivery Systems: Nanocarriers for Enhanced Bioavailability

Addressing the central challenges of poor oral bioavailability and limited BBB penetration is a primary focus of current research. The most promising strategy involves the development of advanced drug delivery systems.

• Rationale: The goal of these systems is to protect Trehalose from enzymatic degradation in the gut and facilitate its transport across biological barriers like the BBB.
• Approaches: Research is centered on trehalose-containing nanocarriers, such as nanoparticles and nanogels. In these systems, Trehalose is either physically encapsulated within the carrier or chemically conjugated to its surface. Preclinical studies have shown that these nanocarriers can successfully deliver Trehalose to target cells, effectively stimulate autophagy, and produce therapeutic effects in animal models of diseases like atherosclerosis, demonstrating proof-of-concept for this approach.

7.3. Trehalose Analogues: The Next Frontier in Research and Development

Another exciting avenue of research involves the rational design and synthesis of Trehalose analogues to create molecules with novel or enhanced properties.

• Rationale: By strategically modifying the Trehalose structure, it is possible to tune its characteristics for specific applications.
• Applications:
• Diagnostics: Analogues tagged with fluorescent probes have been developed for the specific imaging and detection of pathogens like Mycobacterium tuberculosis, which utilize Trehalose in their cell walls.
• Therapeutics: Some analogues have been designed to act as inhibitors of essential metabolic pathways in pathogens, offering potential as novel antimycobacterial agents. Other modified forms, such as trehalose mono-esters, have shown immunoregulatory properties and are being investigated as adjuvants to enhance vaccine efficacy.
• Food Science: Analogues such as lactotrehalose, which are resistant to hydrolysis by human trehalase, are being explored as potential low-calorie, prebiotic sweeteners that could offer health benefits without contributing to caloric intake.

7.4. Expert Synthesis and Strategic Perspective

The analysis of Trehalose reveals a molecule with two distinct and divergent trajectories, each with its own risk profile and market potential.

• The Dual Trajectory:

1. The Established Path: The first trajectory is that of a mature, commercially successful, and low-risk molecule used in applications where systemic pharmacokinetics are irrelevant. This includes its role as a critical excipient for stabilizing biologics and its use in topical ophthalmic solutions for Dry Eye Syndrome. In these areas, Trehalose has a proven track record, a clear mechanism of action (bioprotection), and an established market.
2. The Investigational Path: The second trajectory is a high-risk, high-reward pursuit of systemic therapies for major unmet medical needs, primarily neurodegenerative diseases. This path is fraught with significant scientific and clinical challenges, including the fundamental controversy over its autophagy mechanism and the profound difficulty of delivering the drug to the CNS in therapeutic concentrations.

• Critical Path Forward: The future success of Trehalose as a systemic therapeutic is not guaranteed and depends on achieving several critical milestones. The strategic path forward must prioritize the following:

1. Elucidation of Mechanism: There is an urgent need for definitive in vivo studies that clarify its mechanism of action in the context of neurodegeneration. Resolving the autophagy induction versus flux blockage debate is paramount for building a solid, mechanism-based therapeutic rationale.
2. Viable Delivery Technology: For indications beyond rare diseases treated with high-dose IV infusions, the development of a viable delivery system is essential. A successful oral nanocarrier or a formulation that significantly enhances BBB penetration would be a transformative breakthrough, unlocking a much broader therapeutic potential.
3. Pivotal Clinical Proof-of-Concept: The ongoing pivotal trials in SCA and ALS are critical. Positive outcomes in these studies would provide the first definitive human proof-of-concept for Trehalose as a disease-modifying agent in neurodegeneration, validating the entire investigational platform and likely catalyzing further investment and research into broader indications.

In conclusion, Trehalose stands as a molecule of immense versatility. Its exceptional safety profile provides a firm foundation for development. While its success in local and excipient applications is already secured, its journey to becoming a mainstream systemic therapeutic requires navigating substantial, though not insurmountable, scientific and formulation hurdles. The coming years of clinical and technological development will be decisive in determining whether its full therapeutic potential can be realized.

Works cited

1. Trehalose | C12H22O11 | CID 7427 - PubChem, accessed September 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Trehalose
2. TREHALOSE profile page | Open Targets Platform, accessed September 17, 2025, https://platform.opentargets.org/drug/CHEMBL1236395
3. D(+)-Trehalose anhydrous - Chem-Impex, accessed September 17, 2025, https://www.chemimpex.com/products/31116
4. Trehalose | 99-20-7 - ChemicalBook, accessed September 17, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8210805.htm
5. D-(+)-Trehalose Anhydrous | CAS 99-20-7 | SCBT - Santa Cruz Biotechnology, accessed September 17, 2025, https://www.scbt.com/p/d-plus-trehalose-anhydrous-99-20-7
6. D-Trehalose-Anhydrous | CAS 99-20-7 | TCI-T0832 | Spectrum Chemical, accessed September 17, 2025, https://www.spectrumchemical.com/d-trehalose-anhydrous-tci-t0832
7. Study Details | NCT04663854 | Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE) | ClinicalTrials.gov, accessed September 17, 2025, https://www.clinicaltrials.gov/study/NCT04663854
8. Mechanism of neuroprotection by trehalose: controversy ..., accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6003909/
9. Trehalose - Wikipedia, accessed September 17, 2025, https://en.wikipedia.org/wiki/Trehalose
10. Tailoring Trehalose for Biomedical and Biotechnological Applications - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5718624/
11. Trehalose: A Powerful Excipient in the Formulation Toolbox, accessed September 17, 2025, https://drug-dev.com/trehalose-a-powerful-excipient-in-the-formulation-toolbox/
12. Trehalose: A review of properties, history of use and human tolerance, and results of multiple safety studies - ResearchGate, accessed September 17, 2025, https://www.researchgate.net/publication/11309748_Trehalose_A_review_of_properties_history_of_use_and_human_tolerance_and_results_of_multiple_safety_studies
13. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3102588/
14. CAS RN | 99-20-7 - Thermo Fisher Scientific, accessed September 17, 2025, https://www.thermofisher.com/search/cas/99-20-7
15. [1H,13C] 2D NMR Spectrum (DB12310) | DrugBank Online, accessed September 17, 2025, https://go.drugbank.com/spectra/nmr_two_d/1568
16. Full article: Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology - Taylor & Francis Online, accessed September 17, 2025, https://www.tandfonline.com/doi/full/10.2147/OPTH.S18827
17. The Importance of Trehalose Sugar - Biomedical Journal of Scientific & Technical Research, accessed September 17, 2025, https://biomedres.us/fulltexts/BJSTR.MS.ID.003608.php
18. Trehalose: an intriguing disaccharide with potential for medical appli ..., accessed September 17, 2025, https://www.dovepress.com/trehalose-an-intriguing-disaccharide-with-potential-for-medical-applic-peer-reviewed-fulltext-article-OPTH
19. Trehalose: Neuroprotective Effects and Mechanisms—An Updated Review - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11503274/
20. Trehalose: Neuroprotective Effects and Mechanisms—An Updated Review - MDPI, accessed September 17, 2025, https://www.mdpi.com/2673-4087/5/4/32
21. Synthesis and Application of Trehalose Materials | JACS Au - ACS Publications, accessed September 17, 2025, https://pubs.acs.org/doi/10.1021/jacsau.2c00309
22. Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and Alpha-Synuclein - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/17182613/
23. Trehalose and Neurodegeneration: A Review of Its Role in Autophagy, Protein Aggregation, and Neuroprotection | ASME Open J. Engineering, accessed September 17, 2025, https://asmedigitalcollection.asme.org/openengineering/article/1219418/Trehalose-and-Neurodegeneration-A-Review-of-Its
24. Profiling neuroprotective potential of trehalose in animal models of neurodegenerative diseases: a systematic review - PMC - PubMed Central, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9838167/
25. Glucose and trehalose metabolism through the cyclic pentose phosphate pathway shapes pathogen resistance and host protection in Drosophila | PLOS Biology - Research journals, accessed September 17, 2025, https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002299
26. Mechanism of neuroprotection by trehalose: Controversy surrounding autophagy induction, accessed September 17, 2025, https://www.researchgate.net/publication/325783720_Mechanism_of_neuroprotection_by_trehalose_Controversy_surrounding_autophagy_induction
27. pmc.ncbi.nlm.nih.gov, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6003909/#:~:text=Trehalose%20blocks%20autophagic%20flux%20from,e.g.%2C%20through%20influencing%20gut%20microbiota.
28. Trehalose Granted Orphan Drug Designation for Treatment of Patients with ALS, accessed September 17, 2025, https://www.neurologylive.com/view/trehalose-granted-orphan-drug-designation-for-treatment-of-patients-with-als
29. TREHALOSE - INCHEM, accessed September 17, 2025, https://www.inchem.org/documents/jecfa/jecmono/v46je05.htm
30. Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study - Frontiers, accessed September 17, 2025, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.670935/full
31. Trehalose: A Breakthrough Ingredient for Dry Eye Relief - Clarity Eyecare, accessed September 17, 2025, https://clarityeyecare.ca/trehalose-a-breakthrough-ingredient-for-dry-eye-relief/
32. Trehalose eye drops in the treatment of dry eye syndrome - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/12414409/
33. FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatment - Practical Neurology, accessed September 17, 2025, https://practicalneurology.com/news/fda-accepts-investigational-new-drug-application-and-grants-fast-track-designation-of-trehalose-for-spinocerebellar-ataxia-treatment/2469747/
34. First Participant in Phase 2/3 study of Trehalose Injection in Spinocerebellar Ataxia, accessed September 17, 2025, https://practicalneurology.com/news/first-participant-in-phase-23-study-of-trehalose-injection-in-spinocerebellar-ataxia/2470055/
35. Determination of trehalose by ion chromatography and its application to a pharmacokinetic study in rats after intramuscular injection - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/30063249/
36. European Medicines Agency grants trehalose orphan drug designation for the treatment of amyotrophic lateral sclerosis, accessed September 17, 2025, https://www.medicinesresources.nhs.uk/european-medicines-agency-grants-trehalose-orphan-drug-designation-for-the-treatment-of-amyotrophic-lateral-sclerosis-2.html
37. Using trehalose to prevent and treat metabolic function: effectiveness and mechanisms, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8864729/
38. Trehalose & Eye Care - Review of Ophthalmology, accessed September 17, 2025, https://www.reviewofophthalmology.com/CMSDocuments/2018/05/rp0518_theraMDi.pdf
39. Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory m | OPTH, accessed September 17, 2025, https://www.dovepress.com/trehalosehyaluronate-eyedrop-effects-on-ocular-surface-inflammatory-ma-peer-reviewed-fulltext-article-OPTH
40. Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study - MDPI, accessed September 17, 2025, https://www.mdpi.com/2077-0383/10/20/4699
41. (PDF) Hyaluronic Acid/Trehalose Ophthalmic Solution in Reducing Post-Cataract Surgery Dry Eye Signs and Symptoms: A Prospective, Interventional, Randomized, Open-Label Study - ResearchGate, accessed September 17, 2025, https://www.researchgate.net/publication/355496525_Hyaluronic_AcidTrehalose_Ophthalmic_Solution_in_Reducing_Post-Cataract_Surgery_Dry_Eye_Signs_and_Symptoms_A_Prospective_Interventional_Randomized_Open-Label_Study
42. Search Orphan Drug Designations and Approvals - FDA, accessed September 17, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=442014
43. Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia - PR Newswire, accessed September 17, 2025, https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-fda-acceptance-of-investigational-new-drug-application-and-grant-of-fast-track-designation-for-sls-005-iv-trehalose-for-the-treatment-of-spinocerebellar-ataxia-301417731.html
44. Study Details | NCT04399265 | Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3, accessed September 17, 2025, https://clinicaltrials.gov/study/NCT04399265
45. HEALEY ALS Platform Trial - Regimen E Trehalose NCT05136885 Document Date: 10 Oct 2023 - ClinicalTrials.gov, accessed September 17, 2025, https://cdn.clinicaltrials.gov/large-docs/85/NCT05136885/SAP_001.pdf
46. HEALEY ALS Platform Trial - Regimen E Trehalose NCT05136885, accessed September 17, 2025, https://cdn.clinicaltrials.gov/large-docs/85/NCT05136885/Prot_000.pdf
47. Alzheimer Disease Unknown Status Phase 1 Trials for Trehalose (DB12310) - DrugBank, accessed September 17, 2025, https://go.drugbank.com/indications/DBCOND0003388/clinical_trials/DB12310?phase=1&status=unknown_status
48. Paralysis agitans Unknown Status Phase 4 Trials for Trehalose (DB12310) - DrugBank, accessed September 17, 2025, https://go.drugbank.com/indications/DBCOND0025481/clinical_trials/DB12310?phase=4&status=unknown_status
49. Study Details | NCT05355064 | Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease | ClinicalTrials.gov, accessed September 17, 2025, https://clinicaltrials.gov/study/NCT05355064
50. Study Details | NCT02800161 | Trehalose as add-on Therapy in ..., accessed September 17, 2025, https://www.clinicaltrials.gov/study/NCT02800161
51. Trehalose and Dry Eye Disease: A Comprehensive Systematic Review of Randomized Controlled Trials - MDPI, accessed September 17, 2025, https://www.mdpi.com/2077-0383/12/23/7301
52. Trehalose eye drops found effective for dry eye syndrome - Ophthalmology Times, accessed September 17, 2025, https://www.ophthalmologytimes.com/view/trehalose-eye-drops-found-effective-dry-eye-syndrome
53. Trehalose and Dry Eye Disease: A Comprehensive Systematic Review of Randomized Controlled Trials - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/38068353/
54. (PDF) Trehalose and Dry Eye Disease: A Comprehensive Systematic Review of Randomized Controlled Trials - ResearchGate, accessed September 17, 2025, https://www.researchgate.net/publication/375974595_Trehalose_and_Dry_Eye_Disease_A_Comprehensive_Systematic_Review_of_Randomized_Controlled_Trials
55. Randomized controlled trial of trehalose: An efficient autophagic bioprotectant in the management of dry eye disease - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8259516/
56. Thealoz Duo (sodium hyaluronate with trehalose) - Dry eyes - PAD Formulary, accessed September 17, 2025, https://surreyccg.res-systems.net/PADFormularyV1/Profile/Index/7794
57. Commercially Available Eye Drops Containing Trehalose Protect Against Dry Conditions via Autophagy Induction - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8558061/
58. A randomized crossover study comparing trehalose/hyaluronate eyedrops | TCRM - Dove Medical Press, accessed September 17, 2025, https://www.dovepress.com/a-randomized-crossover-study-comparing-trehalosehyaluronate-eyedrops-a-peer-reviewed-fulltext-article-TCRM
59. Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients - PMC - PubMed Central, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6056167/
60. Trehalose - Pharmaceutical Technology, accessed September 17, 2025, https://www.pharmaceutical-technology.com/products/trehalose/
61. Trehalose: current use and future applications - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/21337544/
62. Trehalose: Current Use and Future Applications - Article 2010 - Pharma Excipients, accessed September 17, 2025, https://www.pharmaexcipients.com/news/trehalose-current-use-and-future-applications-article-2010/
63. Human platelets loaded with trehalose survive freeze-drying - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/11448110/
64. Is Trehalose Safe? | TREHA®︎ - Nagase Food Ingredients Worldwide Sites, accessed September 17, 2025, https://www.nagase-foods.com/global/treha/about_treha/is_trehalose_safe/
65. Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/12065209/
66. Novel food information: Trehalose - Canada.ca, accessed September 17, 2025, https://www.canada.ca/en/health-canada/services/food-nutrition/genetically-modified-foods-other-novel-foods/approved-products/trehalose.html
67. Dietary Trehalose as a Bioactive Nutrient - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10054017/
68. Trehalose - Alzheimer's Drug Discovery Foundation, accessed September 17, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Trehalose-Cognitive-Vitality-For-Researchers.pdf
69. Glucose Interactions Checker - Drugs.com, accessed September 17, 2025, https://www.drugs.com/drug-interactions/glucose.html
70. GRAS- Notice GRN 912 Agency Response Letter - FDA, accessed September 17, 2025, https://www.fda.gov/media/153916/download
71. Who We Are | TREHA®︎ - Nagase Food Ingredients Worldwide Sites, accessed September 17, 2025, https://www.nagase-foods.com/global/treha/who_we_are/
72. Decision - 2001/721 - EN - EUR-Lex - European Union, accessed September 17, 2025, https://eur-lex.europa.eu/eli/dec/2001/721/oj/eng
73. ADVISORY COMMITTEE ON NOVEL FOODS AND PROCESSES, accessed September 17, 2025, https://acnfp.food.gov.uk/sites/default/files/mnt/drupal_data/sources/files/multimedia/pdfs/trehafin.pdf
74. Trehalose - Authorised Regulated Food and Feed Products for Great Britain, accessed September 17, 2025, https://data.food.gov.uk/regulated-products/novel_authorisations/novel-140
75. Trehalose SG Supplier - NAGASE Europe, accessed September 17, 2025, https://www.nagase.eu/product/trehalose-sg-2/
76. A453 Final Assessment Exec Summary | Food Standards Australia New Zealand, accessed September 17, 2025, https://www.foodstandards.gov.au/food-standards-code/applications/applicationa453trehaloseasanovelfoodingredient/a453finalassessmente2049
77. JP XVIII THE JAPANESE PHARMACOPOEIA, accessed September 17, 2025, https://www.mhlw.go.jp/content/11120000/000945683.pdf
78. Trehalose-Releasing Nanogels: Study on Trehalose Release and Insights into Selected Biologically Relevant Aspects | Biomacromolecules - ACS Publications, accessed September 17, 2025, https://pubs.acs.org/doi/10.1021/acs.biomac.4c01505
79. Summary of applications for trehalose and its analogues in food, pharmaceutical, cosmetics and agricultural industries. - ResearchGate, accessed September 17, 2025, https://www.researchgate.net/figure/Summary-of-applications-for-trehalose-and-its-analogues-in-food-pharmaceutical_fig1_280032830
80. Trehalose Analogues: Latest Insights in Properties and Biocatalytic Production - MDPI, accessed September 17, 2025, https://www.mdpi.com/1422-0067/16/6/13729